Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy

Thompson, Robert M.; Giuliani, Meredith; Yap, Mei Ling; Atallah, Soha; Le, Lisa W.; Sun, Alexander; Brade, Anthony; Cho, J.; Bezjak, Andrea; Hope, Andrew

doi:10.1097/jto.0000000000000159

Cited by 30 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Haasbeek and colleagues analyzed 15 patients status-post pneumonectomy who subsequently underwent SBRT for a new stage 1 NSCLC, identifying grade ≥3 pneumonitis in 2 of 15 patients (13.3%) [18]. Similarly, Thompson and colleagues report outcomes for a cohort of 13 patients with prior pneumonectomy subsequently treated with SBRT, identifying 2 cases of grade 3+ pneumonitis (15.4%) [17]. …”

Section: Discussionmentioning

confidence: 99%

“…A total of 2 small case series (references 17 -18) address the risk of SBRT in post-pneumonectomy patients, and none specifically evaluate potential risks in lobectomy patients. We present an analysis of 84 consecutively treated patients with T1-T2b NSCLC treated with 88 courses of SBRT for 94 lung tumors, including 17 patients with prior lung resection.…”

Section: Clinical Practice Pointsmentioning

confidence: 99%

“…Scant data address the risk of SBRT in post-pneumonectomy patients [17, 18], and none evaluate potential risks in prior lobectomy patients. The aim of the present analysis is to compare the rates of RP and rates of all lung toxicity following SBRT in patients with and without prior ALR.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection

Hayes

David

et al. 2015

Clinical Lung Cancer

View full text Add to dashboard Cite

Purpose/Objectives Stereotactic body radiation therapy (SBRT) has emerged as a standard treatment for early stage, medically inoperable lung cancer. Limited data evaluate radiation pneumonitis (RP) risk for SBRT following prior anatomic lung resection (ALR). We assess the incidence of RP and all pulmonary toxicity (PT) in patients treated with lung SBRT following ALR and compare to patients without prior ALR. Materials/Methods We reviewed the medical records of 84 consecutively treated patients with T1-T2b NSCLC treated with 88 courses of SBRT for 94 lung tumors from January 2007- December 2014, including 17 patients with prior ALR. Rates of RP and all PT were compared between patients with and without prior ALR. Results At 18.3 months median follow-up (range 1.8- 85.6 months), crude grade 2+ RP rates were 5.9% and 2.8% for patients with and without prior ALR, respectively (p=0.51), with 2-year estimates of freedom from RP of 89% and 97% (p=0.51). Crude rates of all grade 2+ pulmonary toxicity were 11.8% and 2.8% (p=0.11), respectively, with 2-year freedom from PT of 97% and 84%, (p=0.11). The 2 cohorts were well matched by mean lung dose, lung V20 (p=0.86) and prescribed dose (p=0.75). Two-year estimates of local control, cause-specific survival, and OS were similar between cohorts. Conclusions Observed rates of pulmonary toxicity were low among all patients, with a trend toward increased grade 2-3 lung toxicity among patients with prior ALR. Prior ALR did not increase risk of grade 4-5 RP, and SBRT appears safe and effective in this population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Clinical Practice Pointsmentioning

confidence: 99%

See 1 more Smart Citation

Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection

Hayes

David

et al. 2015

Clinical Lung Cancer

View full text Add to dashboard Cite

show abstract

“…Non‐small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide . With the development of radiotherapy, stereotactic ablative radiotherapy (SABR) has become an effective treatment for NSCLC . RTOG 0236 suggested that peripheral stage I non‐small cell tumors treated with SABR could achieve acceptable local control (LC) and overall survival (OS) .…”

Section: Introductionmentioning

confidence: 99%

“…1,2 With the development of radiotherapy, stereotactic ablative radiotherapy (SABR) has become an effective treatment for NSCLC. [3][4][5][6] RTOG 0236 suggested that peripheral stage I non-small cell tumors treated with SABR could achieve acceptable local control (LC) and overall survival (OS). 7 A phase 3 randomized trial comparing SABR with surgery has suggested that SABR was better tolerated and might lead to better OS compared with surgery for operable clinical stage I NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer

et al. 2020

View full text Add to dashboard Cite

Background There is no consensus on the definition or recommended radiotherapy treatment of ultracentral non‐small cell lung cancer (NSCLC). Here, we report our institution's experience in treating ultracentral lung cancer patients with stereotactic ablative radiotherapy (SABR) of 60 Gy in eight fractions. Methods We retrospectively reviewed the outcomes of 21 ultracentral NSCLC patients treated with 60 Gy SABR in eight fractions. We defined ultracentral lung cancer as the planning target volume (PTV) directly abutting or overlapping central structures, including the proximal bronchial tree, heart, and great vessels but not the esophagus. The Kaplan‐Meier method was used to estimate overall survival (OS), progression‐free survival (PFS) and local control (LC). Toxicity was scored per the CTCAE v4.03. Results The median follow‐up time was 15 months, and the median OS was 15 months. The one‐ and two‐year OS rates were 87.5% and 76.6%, respectively. The one‐ and two‐year PFS rates were 71.1% and 64.0%, respectively. The one‐ and two‐year LC rates were 92.9% and 92.9%, respectively. The rate of grade 2 treatment‐related toxicities was 19.1%. There was no grade ≥ 3 treatment‐related toxicity. Conclusion SABR of 60 Gy in eight fractions is feasible for ultracentral NSCLC.

show abstract

Stereotactic Ablative Radiotherapy for Lung Cancers

Özyiğit

Sarı

Yazıcı

et al. 2016

Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies

View full text Add to dashboard Cite

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy

Cited by 30 publications

References 23 publications

Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection

Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection

Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non‐small cell lung cancer

Stereotactic Ablative Radiotherapy for Lung Cancers

Contact Info

Product

Resources

About